Novartis announced that Pluvicto has been approved by the FDA for PSMA-positive metastatic hormone-sensitive prostate cancer, which is expected to drive new standards for the treatment of metastatic prostate cancer.

Zhitongcaijing · 1d ago
Novartis announced that Pluvicto has been approved by the FDA for PSMA-positive metastatic hormone-sensitive prostate cancer, which is expected to drive new standards for the treatment of metastatic prostate cancer.